Search

Your search keyword '"Ghobadi, Armin"' showing total 754 results
Start Over Author "Ghobadi, Armin"
754 results on '"Ghobadi, Armin"'

51. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Oluwole, Olalekan O., additional, Kersten, Marie José, additional, Miklos, David B., additional, Perales, Miguel-Angel, additional, Ghobadi, Armin, additional, Rapoport, Aaron P., additional, Sureda, Anna, additional, Jacobson, Caron A., additional, Farooq, Umar, additional, van Meerten, Tom, additional, Ulrickson, Matthew, additional, Elsawy, Mahmoud, additional, Leslie, Lori A., additional, Chaganti, Sridhar, additional, Dickinson, Michael, additional, Dorritie, Kathleen, additional, Reagan, Patrick M., additional, McGuirk, Joseph, additional, Song, Kevin W., additional, Riedell, Peter A., additional, Minnema, Monique C., additional, Yang, Yin, additional, Vardhanabhuti, Saran, additional, Filosto, Simone, additional, Cheng, Paul, additional, Shahani, Shilpa A., additional, Schupp, Marco, additional, To, Christina, additional, and Locke, Frederick L., additional

Published
2023
Full Text
View/download PDF

53. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

Author

Jacobson, Caron A., Locke, Frederick L., Ma, Long, Asubonteng, Julius, Hu, Zhen-Huan, Siddiqi, Tanya, Ahmed, Sairah, Ghobadi, Armin, Miklos, David Bernard, Lin, Yi, Perales, Miguel-Angel, Lunning, Matthew Alexander, Herr, Megan M., Hill, Brian T., Ganguly, Siddhartha, Dong, Hua, Nikiforow, Sarah, Hooper, Michele, Kawashima, Jun, Xu, Hairong, and Pasquini, Marcelo C.

Published
2022
Full Text
View/download PDF

57. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia

Author

Barnell, Erica K., Newcomer, Kenneth F., Skidmore, Zachary L., Krysiak, Kilannin, Anderson, Sydney R., Wartman, Lukas D., Oh, Stephen T., Welch, John S., Stockerl-Goldstein, Keith E., Vij, Ravi, Cashen, Amanda F., Pusic, Iskra, Westervelt, Peter, Abboud, Camille N., Ghobadi, Armin, Uy, Geoffrey L., Schroeder, Mark A., Dipersio, John F., Politi, Mary C., Spencer, David H., Duncavage, Eric J., Ley, Timothy J., Griffith, Malachi, Jacoby, Meagan A., and Griffith, Obi L.

Published
2021
Full Text
View/download PDF

58. Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Author

Shah, Bijal, Ghobadi, Armin, Oluwole, Olalekan, Logan, Aaron, Boissel, Nicolas, Cassaday, Ryan, Leguay, Thibaut, Bishop, Michael, Topp, Max, Tzachanis, Dimitrios, O'Dwyer, Kristen, Arellano, Martha, Lin, Yi, Baer, Maria, Schiller, Gary, Park, Jae, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique, Wierda, William, Deangelo, Daniel, Stiff, Patrick, Jeyakumar, Deepa, Dong, Jinghui, Adhikary, Sabina, Zhou, Lang, Schuberth, Petra, Faghmous, Imi, Masouleh, Behzad Kharabi, Houot, Roch, H. Lee Moffitt Cancer Center and Research Institute, Washington University in Saint Louis (WUSTL), Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Recherche clinique appliquée à l'hématologie (URP_3518), Université Paris Cité (UPCité), Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine, ex- Institut Universitaire Hématologie-IUH) (IRSL), CHU Bordeaux [Bordeaux], University of California [San Diego] (UC San Diego), University of California (UC), Mayo Clinic [Rochester], David Geffen School of Medicine [Los Angeles], University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), Ludwig-Maximilians-Universität München (LMU), California State University [Sacramento], MD Anderson Cancer Center [Houston], The University of Texas Health Science Center at Houston (UTHealth), CHU Pontchaillou [Rennes], Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), and Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Immunology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cell Biology, Hematology, Biochemistry
Published
2022

59. Supplementary Figure S4 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., primary, Dickinson, Michael, primary, Ghobadi, Armin, primary, Elsawy, Mahmoud, primary, van Meerten, Tom, primary, Miklos, David B., primary, Ulrickson, Matthew L., primary, Perales, Miguel-Angel, primary, Farooq, Umar, primary, Wannesson, Luciano, primary, Leslie, Lori, primary, Kersten, Marie José, primary, Jacobson, Caron A., primary, Pagel, John M., primary, Wulf, Gerald, primary, Johnston, Patrick, primary, Rapoport, Aaron P., primary, Du, Linqiu, primary, Vardhanabhuti, Saran, primary, Filosto, Simone, primary, Shah, Jina, primary, Snider, Julia T., primary, Cheng, Paul, primary, To, Christina, primary, Oluwole, Olalekan O., primary, and Sureda, Anna, primary

Published
2023
Full Text
View/download PDF

60. Supplementary Tables S1-S11 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., primary, Dickinson, Michael, primary, Ghobadi, Armin, primary, Elsawy, Mahmoud, primary, van Meerten, Tom, primary, Miklos, David B., primary, Ulrickson, Matthew L., primary, Perales, Miguel-Angel, primary, Farooq, Umar, primary, Wannesson, Luciano, primary, Leslie, Lori, primary, Kersten, Marie José, primary, Jacobson, Caron A., primary, Pagel, John M., primary, Wulf, Gerald, primary, Johnston, Patrick, primary, Rapoport, Aaron P., primary, Du, Linqiu, primary, Vardhanabhuti, Saran, primary, Filosto, Simone, primary, Shah, Jina, primary, Snider, Julia T., primary, Cheng, Paul, primary, To, Christina, primary, Oluwole, Olalekan O., primary, and Sureda, Anna, primary

Published
2023
Full Text
View/download PDF

61. Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., primary, Dickinson, Michael, primary, Ghobadi, Armin, primary, Elsawy, Mahmoud, primary, van Meerten, Tom, primary, Miklos, David B., primary, Ulrickson, Matthew L., primary, Perales, Miguel-Angel, primary, Farooq, Umar, primary, Wannesson, Luciano, primary, Leslie, Lori, primary, Kersten, Marie José, primary, Jacobson, Caron A., primary, Pagel, John M., primary, Wulf, Gerald, primary, Johnston, Patrick, primary, Rapoport, Aaron P., primary, Du, Linqiu, primary, Vardhanabhuti, Saran, primary, Filosto, Simone, primary, Shah, Jina, primary, Snider, Julia T., primary, Cheng, Paul, primary, To, Christina, primary, Oluwole, Olalekan O., primary, and Sureda, Anna, primary

Published
2023
Full Text
View/download PDF

62. Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD

Author

McKenna, Marshall, primary, Epperla, Narendranath, additional, Ghobadi, Armin, additional, Liu, Jieqi, additional, Lazaryan, Aleksandr, additional, Ibrahim, Uroosa, additional, Jacobson, Caron A., additional, Naik, Seema G., additional, Nastoupil, Loretta, additional, Chowdhury, Sayan Mullick, additional, Voorhees, Timothy J., additional, Jacobs, Miriam T., additional, Farooq, Umar, additional, Osman, Keren, additional, Olszewski, Adam J., additional, Ahmed, Sairah, additional, and Evens, Andrew M., additional

Published
2023
Full Text
View/download PDF

63. Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes

Author

Jacoby, Meagan A., primary, Welch, John S., additional, Westervelt, Peter, additional, Christopher, Matthew, additional, Uy, Geoffrey L., additional, Vij, Ravi, additional, Stockerl-Goldstein, Keith E., additional, Kahl, Brad S., additional, Pusic, Iskra, additional, DiPersio, John F., additional, Schroeder, Mark A., additional, Kim, Miriam Y., additional, Fehniger, Todd A., additional, Ghobadi, Armin, additional, Gu, Christine J., additional, Anderson, Wade, additional, Vanderlaag, Kathryn, additional, Ali, Kamran, additional, Pataki, Camille, additional, and Lacher, Markus D., additional

Published
2023
Full Text
View/download PDF

64. Abstract 5879: Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma

Author

Mattie, Michael D., primary, Perbost, Regis, additional, Turcan, Sarah, additional, Danan, Corinne, additional, Locke, Frederick L., additional, Neelapu, Sattva S., additional, Miklos, David B., additional, Jacobson, Caron A., additional, Lekakis, Lazaros J., additional, Lin, Yi, additional, Ghobadi, Armin, additional, Kim, Jenny J., additional, Wang, Zixing, additional, Xue, Allen, additional, Filosto, Simone, additional, Scholler, Nathalie, additional, and Galon, Jerome, additional

Published
2023
Full Text
View/download PDF

68. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Author

Cooper, Matthew L, Choi, Jaebok, Staser, Karl, Ritchey, Julie K, Devenport, Jessica M, Eckardt, Kayla, Rettig, Michael P, Wang, Bing, Eissenberg, Linda G, Ghobadi, Armin, Gehrs, Leah N, Prior, Julie L, Achilefu, Samuel, Miller, Christopher A, Fronick, Catrina C, O’Neal, Julie, Gao, Feng, Weinstock, David M, Gutierrez, Alejandro, Fulton, Robert S, and DiPersio, John F

Published
2018
Full Text
View/download PDF

69. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., additional, Dickinson, Michael, additional, Ghobadi, Armin, additional, Elsawy, Mahmoud, additional, van Meerten, Tom, additional, Miklos, David B., additional, Ulrickson, Matthew L., additional, Perales, Miguel-Angel, additional, Farooq, Umar, additional, Wannesson, Luciano, additional, Leslie, Lori, additional, Kersten, Marie José, additional, Jacobson, Caron A., additional, Pagel, John M., additional, Wulf, Gerald, additional, Johnston, Patrick, additional, Rapoport, Aaron P., additional, Du, Linqiu, additional, Vardhanabhuti, Saran, additional, Filosto, Simone, additional, Shah, Jina, additional, Snider, Julia T., additional, Cheng, Paul, additional, To, Christina, additional, Oluwole, Olalekan O., additional, and Sureda, Anna, additional

Published
2023
Full Text
View/download PDF

70. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

Author

Neelapu, Sattva S., primary, Jacobson, Caron A., additional, Ghobadi, Armin, additional, Miklos, David B, additional, Lekakis, Lazaros J., additional, Oluwole, Olalekan O., additional, Lin, Yi, additional, Braunschweig, Ira, additional, Hill, Brian T., additional, Timmerman, John M., additional, Deol, Abhinav, additional, Reagan, Patrick M, additional, Stiff, Patrick Joseph, additional, Flinn, Ian W., additional, Farooq, Umar, additional, Goy, Andre, additional, McSweeney, Peter, additional, Munoz, Javier, additional, Siddiqi, Tanya, additional, Chavez, Julio C., additional, Herrera, Alex F., additional, Bartlett, Nancy L., additional, Bot, Adrian A., additional, Shen, Rhine R., additional, Dong, Jinghui, additional, Singh, Kanwarjit, additional, Miao, Harry, additional, Kim, Jenny J., additional, Zheng, Yan, additional, and Locke, Frederick L., additional

Published
2023
Full Text
View/download PDF

72. Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study

Author

Ghobadi, Armin, primary, Muñoz, Javier, additional, Westin, Jason R., additional, Locke, Frederick L., additional, Miklos, David B., additional, Rapoport, Aaron P., additional, Perales, Miguel-Angel, additional, Reagan, Patrick M., additional, McGuirk, Joseph P., additional, Jacobson, Caron A., additional, Kersten, Marie José, additional, Avivi, Irit, additional, Peng, Andrew, additional, Schupp, Marco, additional, To, Christina, additional, and Oluwole, Olalekan O., additional

Published
2023
Full Text
View/download PDF

73. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R+CT) (ALLELE)

Author

Beitinjaneh, Amer, primary, Baiocchi, Robert, additional, Chaganti, Sridhar, additional, Choquet, Sylvain, additional, Dierickx, Daan, additional, Dinavahi, Rajani, additional, Gamelin, Laurence, additional, Ghobadi, Armin, additional, Guzman-Becerra, Norma, additional, Joshi, AJ, additional, Mahadeo, Kris Michael, additional, Mehta, Dr. Aditi, additional, Nikiforow, Sarah, additional, Reshef, Ran, additional, Ye, Wei, additional, and Prockop, Susan, additional

Published
2023
Full Text
View/download PDF

74. Subgroup Analyses of Kte-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Adult Patients (Pts) with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in Zuma-3

Author

Shah, Bijal D., primary, Cassaday, Ryan D., additional, Park, Jae H., additional, Houot, Roch, additional, Oluwole, Olalekan O., additional, Logan, Aaron C., additional, Boissel, Nicolas, additional, Leguay, Thibaut, additional, Bishop, Michael R., additional, Topp, Max S., additional, Tzachanis, Dimitrios, additional, O’Dwyer, Kristen M., additional, Arellano, Martha L., additional, Lin, Yi, additional, Baer, Maria R., additional, Schiller, Gary J., additional, Subklewe, Marion, additional, Abedi, Mehrdad, additional, Minnema, Monique C., additional, Wierda, William G., additional, DeAngelo, Daniel J., additional, Stiff, Patrick, additional, Jeyakumar, Deepa, additional, Dong, Jinghui, additional, Adhikary, Sabina, additional, Zhou, Lang, additional, Schuberth, Petra C., additional, Masouleh, Behzad Kharabi, additional, and Ghobadi, Armin, additional

Published
2023
Full Text
View/download PDF

75. Additional file 1 of Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

Author

Shah, Bijal D., Ghobadi, Armin, Oluwole, Olalekan O., Logan, Aaron C., Boissel, Nicolas, Cassaday, Ryan D., Leguay, Thibaut, Bishop, Michael R., Topp, Max S., Tzachanis, Dimitrios, O’Dwyer, Kristen M., Arellano, Martha L., Lin, Yi, Baer, Maria R., Schiller, Gary J., Park, Jae H., Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C., Wierda, William G., DeAngelo, Daniel J., Stiff, Patrick, Jeyakumar, Deepa, Dong, Jinghui, Adhikary, Sabina, Zhou, Lang, Schuberth, Petra C., Faghmous, Imi, Masouleh, Behzad Kharabi, and Houot, Roch

Abstract

Additional file 1. Supplementary Appendix.

Published
2023
Full Text
View/download PDF

76. Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV+) Leiomyosarcomas (LMS)

Author

Jiménez-Kurlander, Lauren S, primary, Behr, Gerald, additional, Bunin, Nancy J, additional, Doubrovina, Ekaterina, additional, Dinavahi, Rajani, additional, Gamelin, Laurence, additional, Ghobadi, Armin, additional, Mascarenhas, Leo, additional, Nikiforow, Sarah, additional, O'Reilly, Richard J, additional, Price, Anita, additional, Shulkin, Barry, additional, Srinivasan, Ashok, additional, Suser, Stephanie, additional, Wahlstrom, Justin, additional, Xing, Baodong, additional, and Prockop, Susan, additional

Published
2022
Full Text
View/download PDF

77. Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Author

Lunning, Matthew A., primary, Wang, Hai-Lin, additional, Hu, Zhen-Huan, additional, Locke, Frederick L., additional, Siddiqi, Tanya, additional, Jacobson, Caron A., additional, Ahmed, Sairah, additional, Miklos, David B., additional, Lin, Yi, additional, Hill, Brian T., additional, Ghobadi, Armin, additional, Neelapu, Sattva S., additional, Westin, Jason, additional, Miao, Harry, additional, Shahani, Shilpa, additional, Patel, Anik R., additional, Spooner, Clare, additional, Fu, Christine, additional, Xu, Hairong, additional, and Pasquini, Marcelo C, additional

Published
2022
Full Text
View/download PDF

78. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Author

Mahadeo, Kris Michael, primary, Baiocchi, Robert A., additional, Beitinjaneh, Amer, additional, Chaganti, Sridhar, additional, Choquet, Sylvain, additional, Dierickx, Daan, additional, Dinavahi, Rajani, additional, Gamelin, Laurence, additional, Ghobadi, Armin, additional, Guzman-Becerra, Norma, additional, Joshi, Manher, additional, Mehta, Aditi, additional, Nikiforow, Sarah, additional, Reshef, Ran, additional, Ye, Wei, additional, and Prockop, Susan, additional

Published
2022
Full Text
View/download PDF

79. Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Author

Ghobadi, Armin, primary, Munoz, Javier, additional, Westin, Jason, additional, Locke, Frederick L., additional, Miklos, David B., additional, Rapoport, Aaron P., additional, Perales, Miguel-Angel, additional, Reagan, Patrick M., additional, McGuirk, Joseph P., additional, Jacobson, Caron A., additional, Kersten, Marie José, additional, Avivi, Irit, additional, Peng, Andrew, additional, Schupp, Marco, additional, To, Christina, additional, and Oluwole, Olalekan O., additional

Published
2022
Full Text
View/download PDF

80. CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Author

McGuirk, Joseph P., primary, Tam, Constantine S., additional, Kröger, Nicolaus, additional, Riedell, Peter A., additional, Murthy, Hemant S., additional, Ho, Phoebe Joy, additional, Maakaron, Joseph E., additional, Waller, Edmund K., additional, Awan, Farrukh T., additional, Shaughnessy, Paul J., additional, Ghobadi, Armin, additional, Bishop, Michael R., additional, Alfonso-Pierola, Ana, additional, Dickinson, Michael, additional, Ramakrishnan Geethakumari, Praveen, additional, Ross, Ainsley, additional, Stevens, William, additional, Xu, Huansheng, additional, Ma, Anna, additional, Cohen, Sarah Beaussant, additional, Maziarz, Richard T., additional, and Bachier, Carlos, additional

Published
2022
Full Text
View/download PDF

81. Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Author

Schroeder, Mark A., primary, Choi, Jaebok, additional, Atluri, Himachandana, additional, Atkins, Jordan, additional, Harding, Melinda, additional, Eisele, Jeremy, additional, Gao, Feng, additional, Abboud, Ramzi, additional, Abboud, Camille, additional, Cashen, Amanda F., additional, Christopher, Matthew, additional, Fehniger, Todd A., additional, Ferraro, Francesca, additional, Ghobadi, Armin, additional, Jacoby, Meagan A., additional, Pusic, Iskra, additional, Stockerl-Goldstein, Keith E, additional, Uy, Geoffrey L., additional, Vij, Ravi, additional, Walter, Matthew J, additional, Westervelt, Peter, additional, and DiPersio, John F., additional

Published
2022
Full Text
View/download PDF

82. Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Author

Caimi, Paolo F, primary, Di Trani, Martina, additional, Ghobadi, Armin, additional, Reese, Jane, additional, Tomlinson, Benjamin, additional, Otegbeye, Folashade, additional, Boughan, Kirsten M, additional, Gallogly, Molly, additional, Metheny, Leland, additional, Cooper, Brenda W., additional, Dropulic, Boro, additional, de Lima, Marcos J.G., additional, and Carlo-Stella, Carmelo, additional

Published
2022
Full Text
View/download PDF

83. A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma

Author

Ghobadi, Armin, primary, Budde, L. Elizabeth, additional, Galal, Ahmed, additional, Stermer, Kristina, additional, Bierly, Allison, additional, Ferrando-Martinez, Sara, additional, Lee, Byung Ha, additional, and DiPersio, John F., additional

Published
2022
Full Text
View/download PDF

84. Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Author

Locke, Frederick L., primary, Hu, Zhen-Huan, additional, Siddiqi, Tanya, additional, Jacobson, Caron A., additional, Nikiforow, Sarah, additional, Ahmed, Sairah, additional, Miklos, David B., additional, Lin, Yi, additional, Lunning, Matthew A., additional, Hill, Brian T., additional, Ghobadi, Armin, additional, Miao, Harry, additional, Shahani, Shilpa, additional, Spooner, Clare, additional, Fu, Christine, additional, Patel, Anik R., additional, Xu, Hairong, additional, and Pasquini, Marcelo C, additional

Published
2022
Full Text
View/download PDF

85. Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome

Author

Butt, Omar H., primary, Zhou, Alice Y., additional, Caimi, Paolo F., additional, Luckett, Patrick H., additional, Wisch, Julie K., additional, Derenoncourt, Paul-Robert, additional, Lee, Kenneth, additional, Wu, Gregory F., additional, de Lima, Marcos J. G., additional, Campian, Jian L., additional, Frank, Matthew J., additional, DiPersio, John F., additional, Ghobadi, Armin, additional, and Ances, Beau M., additional

Published
2022
Full Text
View/download PDF

86. 1454 Multiomics and multimodal analysis approach to construct a diffuse large B cell lymphoma atlas of tumor microenvironment for predictive modeling

Author

Mattie, Mike, primary, Perbost, Regis, additional, Turcan, Sarah, additional, Danan, Corinne, additional, Locke, Frederick, additional, Neelapu, Sattva, additional, Miklos, David, additional, Jacobson, Caron, additional, Lekakis, Lazaros, additional, Lin, Yi, additional, Ghobadi, Armin, additional, Kim, Jenny, additional, Wang, Zixing, additional, Xue, Allen, additional, Filosto, Simone, additional, Scholler, Nathalie, additional, and Galon, Jérôme, additional

Published
2022
Full Text
View/download PDF

87. 776 ITIL-306–201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor

Author

Ward, Jeffrey, primary, Ghobadi, Armin, additional, Liao, John, additional, Schoenfeld, Adam, additional, Tykodi, Scott, additional, Jiang, Yizhou, additional, Gall, John Le, additional, Alvarez-Rodriguez, Ruben, additional, Sherman, Marika, additional, Singson, Tiffany, additional, and McLeroy, Jeffrey, additional

Published
2022
Full Text
View/download PDF

88. Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies

Author

Ghobadi, Armin, primary, Landmann, Jack H., additional, Carter, Alun, additional, Cooper, Matthew L., additional, Selli, Mehmet Emrah, additional, Chang, Jufang, additional, Baker, Matthew, additional, Miller, Christopher A., additional, Ferraro, Francesca, additional, Chen, David Y., additional, Smith, Amanda M., additional, LaValle, Taylor A., additional, Duncavage, Eric J., additional, Chou, Justin, additional, Tam, Victor, additional, Benoun, Joseph M., additional, Nater, Jenny, additional, Scholler, Nathalie, additional, Milletti, Francesca, additional, Vezan, Remus, additional, Bot, Adrian, additional, Rossi, John M., additional, and Singh, Nathan, additional

Published
2022
Full Text
View/download PDF

90. Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission

Author

Warlick, Erica D., Paulson, Kristjan, Brazauskas, Ruta, Zhong, Xiaobo, Miller, Alan M., Camitta, Bruce M., George, Biju, Savani, Bipin N., Ustun, Celalettin, Marks, David I., Waller, Edmund K., Baron, Frédéric, Freytes, César O., Socie, Gérard, Akpek, Gorgun, Schouten, Harry C., Lazarus, Hillard M., Horwitz, Edwin M., Koreth, John, Cahn, Jean-Yves, Bornhauser, Martin, Seftel, Matthew, Cairo, Mitchell S., Laughlin, Mary J., Sabloff, Mitchell, Ringdén, Olle, Gale, Robert Peter, Kamble, Rammurti T., Vij, Ravi, Gergis, Usama, Mathews, Vikram, Saber, Wael, Chen, Yi-Bin, Liesveld, Jane L., Cutler, Corey S., Ghobadi, Armin, Uy, Geoffrey L., Eapen, Mary, Weisdorf, Daniel J., and Litzow, Mark R.

Published
2014
Full Text
View/download PDF

91. Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Author

Jaswal, Shama, primary, Sanders, Vanessa, additional, Pullarkat, Priyanka, additional, Teja, Stephanie, additional, Salter, Amber, additional, Watkins, Marcus P., additional, Atagu, Norman, additional, Ludwig, Daniel R., additional, Mhlanga, Joyce, additional, Mellnick, Vincent M., additional, Peterson, Linda R., additional, Bartlett, Nancy L., additional, Kahl, Brad S., additional, Fehniger, Todd A., additional, Ghobadi, Armin, additional, Cashen, Amanda F., additional, Mehta-Shah, Neha, additional, and Ippolito, Joseph E., additional

Published
2022
Full Text
View/download PDF

92. Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.

Author

Locke, Frederick L., primary, Siddiqi, Tanya, additional, Jacobson, Caron Alyce, additional, Ghobadi, Armin, additional, Ahmed, Sairah, additional, Miklos, David Bernard, additional, Perales, Miguel-Angel, additional, Munoz, Javier, additional, Logan, Brent, additional, Hu, Zhen-Huan, additional, Miao, Harry H., additional, Singh, Kanwarjit, additional, Shah, Jina, additional, Xu, Hairong, additional, and Pasquini, Marcelo C., additional

Published
2022
Full Text
View/download PDF

93. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

Author

Wierda, William G., primary, Brown, Jennifer, additional, Abramson, Jeremy S., additional, Awan, Farrukh, additional, Bilgrami, Syed F., additional, Bociek, Greg, additional, Brander, Danielle, additional, Chanan-Khan, Asher A., additional, Coutre, Steve E., additional, Davis, Randall S., additional, Eradat, Herbert, additional, Fletcher, Christopher D., additional, Gaballa, Sameh, additional, Ghobadi, Armin, additional, Hamid, Muhammad Saad, additional, Hernandez-Ilizaliturri, Francisco, additional, Hill, Brian, additional, Kaesberg, Paul, additional, Kamdar, Manali, additional, Kaplan, Lawrence D., additional, Khan, Nadia, additional, Kipps, Thomas J., additional, Ma, Shuo, additional, Mato, Anthony, additional, Mosse, Claudio, additional, Schuster, Stephen, additional, Siddiqi, Tanya, additional, Stephens, Deborah M., additional, Ujjani, Chaitra, additional, Wagner-Johnston, Nina, additional, Woyach, Jennifer A., additional, Ye, J. Christine, additional, Dwyer, Mary A., additional, and Sundar, Hema, additional

Published
2022
Full Text
View/download PDF

94. Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).

Author

Westin, Jason, primary, Locke, Frederick L., additional, Dickinson, Michael, additional, Ghobadi, Armin, additional, Elsawy, Mahmoud, additional, van Meerten, Tom, additional, Miklos, David Bernard, additional, Ulrickson, Matthew, additional, Perales, Miguel-Angel, additional, Farooq, Umar, additional, Wannesson, Luciano, additional, Leslie, Lori Ann, additional, Kersten, Marie José, additional, Jacobson, Caron Alyce, additional, Pagel, John M., additional, Wulf, Gerald, additional, Du, Linqiu, additional, Snider, Julia, additional, To, Christina Ann, additional, and Oluwole, Olalekan O., additional

Published
2022
Full Text
View/download PDF

95. Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.

Author

Ghobadi, Armin, primary, Budde, L Elizabeth, additional, Galal, Ahmed, additional, Stermer, Kristina, additional, Austin, TaShara Lynn, additional, Fan, Jean, additional, and DiPersio, John F., additional

Published
2022
Full Text
View/download PDF

96. Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.

Author

Shah, Bijal D., primary, Ghobadi, Armin, additional, Oluwole, Olalekan O., additional, Logan, Aaron, additional, Boissel, Nicolas, additional, Cassaday, Ryan Daniel, additional, Forcade, Edouard, additional, Bishop, Michael Russell, additional, Topp, Max S., additional, Tzachanis, Dimitrios, additional, O'Dwyer, Kristen M., additional, Arellano, Martha Lucia, additional, Lin, Yi, additional, Baer, Maria R., additional, Schiller, Gary J., additional, Zhou, Lang, additional, Schuberth, Petra C., additional, Adhikary, Sabina, additional, Kharabi Masouleh, Behzad, additional, and Houot, Roch, additional

Published
2022
Full Text
View/download PDF

97. Salvage Second Hematopoietic Cell Transplantation in Myeloma

Author

Michaelis, Laura C., Saad, Ayman, Zhong, Xiaobo, Le-Rademacher, Jennifer, Freytes, Cesar O., Marks, David I., Lazarus, Hillard M., Bird, Jennifer M., Holmberg, Leona, Kamble, Rammurti T., Kumar, Shaji, Lill, Michael, Meehan, Kenneth R., Saber, Wael, Schriber, Jeffrey, Tay, Jason, Vogl, Dan T., Wirk, Baldeep, Savani, Bipin N., Gale, Robert P., Vesole, David H., Schiller, Gary J., Abidi, Muneer, Anderson, Kenneth C., Nishihori, Taiga, Kalaycio, Matt E., Vose, Julie M., Moreb, Jan S., Drobyski, William, Munker, Reinhold, Roy, Vivek, Ghobadi, Armin, Holland, H. Kent, Nath, Rajneesh, To, L. Bik, Maiolino, Angelo, Kassim, Adetola A., Giralt, Sergio A., Landau, Heather, Schouten, Harry C., Maziarz, Richard T., Michael, Joseph, Kindwall-Keller, Tamila, Stiff, Patrick J., Gibson, John, Lonial, Sagar, Krishnan, Amrita, Dispenzieri, Angela, and Hari, Parameswaran

Published
2013
Full Text
View/download PDF

98. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

Author

Hong, David S., primary, Butler, Marcus O., additional, Pachynski, Russell K., additional, Sullivan, Ryan, additional, Kebriaei, Partow, additional, Boross-Harmer, Sarah, additional, Ghobadi, Armin, additional, Frigault, Matthew J., additional, Dumbrava, Ecaterina E., additional, Sauer, Amy, additional, Brophy, Francine, additional, Navenot, Jean-Marc, additional, Fayngerts, Svetlana, additional, Wolchinsky, Zohar, additional, Broad, Robyn, additional, Batrakou, Dzmitry G., additional, Wang, Ruoxi, additional, Solis, Luisa M., additional, Duose, Dzifa Yawa, additional, Sanderson, Joseph P., additional, Gerry, Andrew B., additional, Marks, Diane, additional, Bai, Jane, additional, Norry, Elliot, additional, and Fracasso, Paula M., additional

Published
2022
Full Text
View/download PDF

99. Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)

Author

Jacobson, Caron A., primary, Locke, Frederick L., additional, Ghobadi, Armin, additional, Miklos, David B., additional, Lekakis, Lazaros J., additional, Oluwole, Olalekan O., additional, Lin, Yi, additional, Hill, Brian T., additional, Timmerman, John M., additional, Deol, Abhinav, additional, Reagan, Patrick M., additional, Stiff, Patrick, additional, Flinn, Ian W., additional, Farooq, Umar, additional, Goy, Andre H., additional, Muñoz, Javier, additional, Siddiqi, Tanya, additional, Shen, Rhine R, additional, Bot, Adrian, additional, Dong, Jinghui, additional, Singh, Kanwarjit, additional, Spooner, Clare, additional, Karalliyadda, Roshan, additional, Kim, Jenny J., additional, Zheng, Yan, additional, and Neelapu, Sattva S., additional

Published
2022
Full Text
View/download PDF

100. Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium

Author

Muñoz, Javier, primary, Wang, Yucai, additional, Jain, Preetesh, additional, Locke, Frederick L., additional, Maurer, Matthew J, additional, Beitinjaneh, Amer, additional, Frank, Matthew J., additional, Dahiya, Saurabh, additional, McGuirk, Joseph P., additional, Jacobs, Miriam T, additional, Goy, Andre H., additional, Vose, Julie M., additional, Hill, Brian T., additional, Oluwole, Olalekan O., additional, Deol, Abhinav, additional, Shah, Bijal, additional, Paludo, Jonas, additional, Wang, Trent P, additional, Lekakis, Lazaros J., additional, Miklos, David B., additional, Rapoport, Aaron P., additional, Ghobadi, Armin, additional, Neelapu, Sattva S., additional, Lin, Yi, additional, Wang, Michael, additional, and Jain, Michael D, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results